Drug intelligence / Profile preview

Xingdi Kechuanning

Development stage: Unknown
Lead developer: Simcere Pharmaceutical Group
Administration: Oral

Overview

Xingdi Kechuanning is a Traditional Chinese Medicine (TCM) formulation developed by Guizhou Weimen Pharmaceutical for the treatment of respiratory conditions including chronic obstructive pulmonary disease (COPD), acute exacerbations of chronic bronchitis, and asthma. Formulated as a capsule, it is specifically indicated for patients presenting with wind-cold binding the lung and kidney qi deficiency syndromes according to TCM principles. The therapy aims to relieve cough and wheezing by harmonizing lung and kidney functions. It has been evaluated in Phase II clinical trials in China.

Brand names: Xingdi Kechuanning
Other names: Xingdi Kechuanning Capsule杏蒂咳喘宁

Beyond the preview

Go deeper on Xingdi Kechuanning.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xingdi Kechuanning.

Explore the full profile